Transcription factor C/EBP-β mediates downregulation of dipeptidyl-peptidase III expression by interleukin-6 in human glioblastoma cells

FEBS Journal

Volumn 281, Issue 6, 2014, Pages 1629-1641

  Singh, Ratnakar ^a   Sharma, Mehar C ^a   Sarkar, Chitra ^a   Singh, Manmohan ^a   Chauhan, Shyam S ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

brain tumor; gene regulation; metallopeptidase; siRNA; transcription

Indexed keywords

BRAIN TUMOR; GENE REGULATION; METALLOPEPTIDASE; SIRNA; TRANSCRIPTION;

BINDING SITES; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL LINE, TUMOR; DIPEPTIDYL-PEPTIDASES AND TRIPEPTIDYL-PEPTIDASES; DOWN-REGULATION; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MUTAGENESIS, SITE-DIRECTED; PROGNOSIS; PROMOTER REGIONS, GENETIC; RESPONSE ELEMENTS; RNA, MESSENGER; RNA, NEOPLASM; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL;

EID: 84899447693     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12728     Document Type: Article

References (49)

1. Lam SP, Luk JM, Man K, Ng KT, Cheung CK, Rose-John S, &, Lo CM, (2010) Activation of interleukin-6-induced glycoprotein 130/signal transducer and activator of transcription 3 pathway in mesenchymal stem cells enhances hepatic differentiation, proliferation, and liver regeneration. Liver Transpl 16, 1195-1206.
2. Qiu Z, Sweeney DD, Netzeband JG, &, Gruol DL, (1998) Chronic interleukin-6 alters NMDA receptor-mediated membrane responses and enhances neurotoxicity in developing CNS neurons. J Neurosci 18, 10445-10456. (Pubitemid 29016564)
3. Ramsay AJ, Husband AJ, Ramshaw IA, Bao S, Matthaei KI, Koehler G, &, Kopf M, (1994) The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 264, 561-563. (Pubitemid 24185859)
4. Rodriguez Mdel C, Bernad A, &, Aracil M, (2004) Interleukin-6 deficiency affects bone marrow stromal precursors, resulting in defective hematopoietic support. Blood 103, 3349-3354. (Pubitemid 38525663)
5. Mollmann H, Nef HM, &, Troidl C, (2010) 'Turning the right screw': targeting the interleukin-6 receptor to reduce unfavourable tissue remodelling after myocardial infarction. Cardiovasc Res 87, 395-396.
6. De Jongh RF, Vissers KC, Meert TF, Booij LH, De Deyne CS, &, Heylen RJ, (2003) The role of interleukin-6 in nociception and pain. Anesth Analg 96, 1096-1103. (Pubitemid 36359050)
7. Weissenberger J, Loeffler S, Kappeler A, Kopf M, Lukes A, Afanasieva TA, Aguzzi A, &, Weis J, (2004) IL-6 is required for glioma development in a mouse model. Oncogene 23, 3308-3316. (Pubitemid 38669820)
8. Sasaki A, Ishiuchi S, Kanda T, Hasegawa M, &, Nakazato Y, (2001) Analysis of interleukin-6 gene expression in primary human gliomas, glioblastoma xenografts, and glioblastoma cell lines. Brain Tumor Pathol 18, 13-21.
9. Waldner MJ, Foersch S, &, Neurath MF, (2012) Interleukin-6-a key regulator of colorectal cancer development. Int J Biol Sci 8, 1248-1253.
10. Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, &, Hsieh CY, (2003) Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 22, 1517-1527.
11. Li R, Li G, Deng L, Liu Q, Dai J, Shen J, &, Zhang J, (2010) IL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1. Oncol Rep 23, 1553-1559.
12. Liu Q, Li G, Li R, Shen J, He Q, Deng L, Zhang C, &, Zhang J, (2010) IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. J Neurooncol 100, 165-176.
13. Chang CY, Li MC, Liao SL, Huang YL, Shen CC, &, Pan HC, (2005) Prognostic and clinical implication of IL-6 expression in glioblastoma multiforme. J Clin Neurosci 12, 930-933.
14. Prajapati SC, &, Chauhan SS, (2011) Dipeptidyl peptidase III: a multifaceted oligopeptide N-end cutter. FEBS J 278, 3256-3276.
15. Simaga S, Babic D, Osmak M, Sprem M, &, Abramic M, (2003) Tumor cytosol dipeptidyl peptidase III activity is increased with histological aggressiveness of ovarian primary carcinomas. Gynecol Oncol 91, 194-200. (Pubitemid 37188611)
16. Shukla AA, Jain M, &, Chauhan SS, (2010) Ets-1/Elk-1 is a critical mediator of dipeptidyl-peptidase III transcription in human glioblastoma cells. FEBS J 277, 1861-1875.
17. Van Meir E, Sawamura Y, Diserens AC, Hamou MF, &, de Tribolet N, (1990) Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res 50, 6683-6688. (Pubitemid 20348800)
18. Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM, Eyler CE, Elderbroom J, Gallagher J, Schuschu J, et al,. (2009) Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 27, 2393-2404.
19. Loeffler S, Fayard B, Weis J, &, Weissenberger J, (2005) Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. Int J Cancer 115, 202-213. (Pubitemid 40586728)
20. Saidi A, Hagedorn M, Allain N, Verpelli C, Sala C, Bello L, Bikfalvi A, &, Javerzat S, (2009) Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. Int J Cancer 125, 1054-1064.
21. Yamaguchi T, Naruishi K, Arai H, Nishimura F, &, Takashiba S, (2008) IL-6/sIL-6R enhances cathepsin B and L production via caveolin-1-mediated JNK-AP-1 pathway in human gingival fibroblasts. J Cell Physiol 217, 423-432.
22. Tsui KH, Wang SW, Chung LC, Feng TH, Lee TY, Chang PL, &, Juang HH, (2013) Mechanisms by which interleukin-6 attenuates cell invasion and tumorigenesis in human bladder carcinoma cells. Biomed Res Int 2013, 791212, doi: 10.1155/2013/791212
23. Mohamed MM, Cavallo-Medved D, Rudy D, Anbalagan A, Moin K, &, Sloane BF, (2010) Interleukin-6 increases expression and secretion of cathepsin B by breast tumor-associated monocytes. Cell Physiol Biochem 25, 315-324.
24. Margulies L, &, Sehgal PB, (1993) Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBP beta (NF-IL6) activity by p53 species. J Biol Chem 268, 15096-15100. (Pubitemid 23206661)
25. Huang Y, Shinzawa H, Togashi H, Takahashi T, Kuzumaki T, Otsu K, &, Ishikawa K, (1995) Interleukin-6 down-regulates expressions of the aldolase B and albumin genes through a pathway involving the activation of tyrosine kinase. Arch Biochem Biophys 320, 203-209.
26. Poree B, Kypriotou M, Chadjichristos C, Beauchef G, Renard E, Legendre F, Melin M, Gueret S, Hartmann DJ, Mallein-Gerin F, et al,. (2008) Interleukin-6 (IL-6) and/or soluble IL-6 receptor down-regulation of human type II collagen gene expression in articular chondrocytes requires a decrease of Sp1.Sp3 ratio and of the binding activity of both factors to the COL2A1 promoter. J Biol Chem 283, 4850-4865.
27. Pascussi JM, Gerbal-Chaloin S, Pichard-Garcia L, Daujat M, Fabre JM, Maurel P, &, Vilarem MJ, (2000) Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem Biophys Res Commun 274, 707-713. (Pubitemid 30663683)
28. Castell JV, Gomez-Lechon MJ, David M, Hirano T, Kishimoto T, &, Heinrich PC, (1988) Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett 232, 347-350.
29. Andus T, Geiger T, Hirano T, Kishimoto T, Tran-Thi TA, Decker K, &, Heinrich PC, (1988) Regulation of synthesis and secretion of major rat acute-phase proteins by recombinant human interleukin-6 (BSF-2/IL-6) in hepatocyte primary cultures. Eur J Biochem 173, 287-293.
30. Aigueperse C, Val P, Pacot C, Darne C, Lalli E, Sassone-Corsi P, Veyssiere G, Jean C, &, Martinez A, (2001) SF-1 (steroidogenic factor-1), C/EBPbeta (CCAAT/enhancer binding protein), and ubiquitous transcription factors NF1 (nuclear factor 1) and Sp1 (selective promoter factor 1) are required for regulation of the mouse aldose reductase-like gene (AKR1B7) expression in adrenocortical cells. Mol Endocrinol 15, 93-111. (Pubitemid 32156044)
31. Buck M, Zhang L, Halasz NA, Hunter T, &, Chojkier M, (2001) Nuclear export of phosphorylated C/EBPbeta mediates the inhibition of albumin expression by TNF-alpha. EMBO J 20, 6712-6723. (Pubitemid 33134201)
32. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, Sulman EP, Anne SL, Doetsch F, Colman H, et al,. (2010) The transcriptional network for mesenchymal transformation of brain tumours. Nature 463, 318-325.
33. Dentesano G, Straccia M, Ejarque-Ortiz A, Tusell JM, Serratosa J, Saura J, &, Sola C, (2012) Inhibition of CD200R1 expression by C/EBP β in reactive microglial cells. J Neuroinflammation 9, 165.
34. Fields J, &, Ghorpade A, (2012) C/EBP beta regulates multiple IL-1beta-induced human astrocyte inflammatory genes. J Neuroinflammation 9, 177.
35. Luedde T, Duderstadt M, Streetz KL, Tacke F, Kubicka S, Manns MP, &, Trautwein C, (2004) C/EBP beta isoforms LIP and LAP modulate progression of the cell cycle in the regenerating mouse liver. Hepatology 40, 356-365. (Pubitemid 39062853)
36. Smink JJ, Begay V, Schoenmaker T, Sterneck E, de Vries TJ, &, Leutz A, (2009) Transcription factor C/EBPbeta isoform ratio regulates osteoclastogenesis through MafB. EMBO J 28, 1769-1781.
37. Trautwein C, Rakemann T, Pietrangelo A, Plumpe J, Montosi G, &, Manns MP, (1996) C/EBP-beta/LAP controls down-regulation of albumin gene transcription during liver regeneration. J Biol Chem 271, 22262-22270. (Pubitemid 26303863)
38. Akira S, Isshiki H, Sugita T, Tanabe O, Kinoshita S, Nishio Y, Nakajima T, Hirano T, &, Kishimoto T, (1990) A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J 9, 1897-1906.
39. Homma J, Yamanaka R, Yajima N, Tsuchiya N, Genkai N, Sano M, &, Tanaka R, (2006) Increased expression of CCAAT/enhancer binding protein beta correlates with prognosis in glioma patients. Oncol Rep 15, 595-601.
40. Ramji DP, Vitelli A, Tronche F, Cortese R, &, Ciliberto G, (1993) The two C/EBP isoforms, IL-6DBP/NF-IL6 and C/EBP delta/NF-IL6 beta, are induced by IL-6 to promote acute phase gene transcription via different mechanisms. Nucleic Acids Res 21, 289-294. (Pubitemid 23151900)
41. Niehof M, Streetz K, Rakemann T, Bischoff SC, Manns MP, Horn F, &, Trautwein C, (2001) Interleukin-6-induced tethering of STAT3 to the LAP/C/EBPbeta promoter suggests a new mechanism of transcriptional regulation by STAT3. J Biol Chem 276, 9016-9027.
42. Chen GK, Sale S, Tan T, Ermoian RP, &, Sikic BI, (2004) CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAAT box in human cancer cells. Mol Pharmacol 65, 906-916. (Pubitemid 38420496)
43. Oya M, Horiguchi A, Mizuno R, Marumo K, &, Murai M, (2003) Increased activation of CCAAT/enhancer binding protein-beta correlates with the invasiveness of renal cell carcinoma. Clin Cancer Res 9, 1021-1027. (Pubitemid 36323706)
44. Mir RA, &, Chauhan SS, (2011) Down regulation of a matrix degrading cysteine protease cathepsin L, by acetaldehyde: role of C/EBPalpha. PLoS ONE 6, e20768.
45. Bezerra GA, Dobrovetsky E, Viertlmayr R, Dong A, Binter A, Abramic M, Macheroux P, Dhe-Paganon S, &, Gruber K, (2012) Entropy-driven binding of opioid peptides induces a large domain motion in human dipeptidyl peptidase III. Proc Natl Acad Sci U S A 109, 6525-6530.
46. Barsun M, Jajcanin N, Vukelic B, Spoljaric J, &, Abramic M, (2007) Human dipeptidyl peptidase III acts as a post-proline-cleaving enzyme on endomorphins. Biol Chem 388, 343-348. (Pubitemid 46364475)
47. Sato H, Kimura K, Yamamoto Y, &, Hazato T, (2003) Activity of DPP III in human cerebrospinal fluid derived from patients with pain. Masui 52, 257-263. (Pubitemid 36422863)
48. Tchirkov A, Khalil T, Chautard E, Mokhtari K, Veronese L, Irthum B, Vago P, Kemeny JL, &, Verrelle P, (2007) Interleukin-6 gene amplification and shortened survival in glioblastoma patients. Br J Cancer 96, 474-476. (Pubitemid 46215219)
49. Rodriguez-Antona C, Bort R, Jover R, Tindberg N, Ingelman-Sundberg M, Gomez-Lechon MJ, &, Castell JV, (2003) Transcriptional regulation of human CYP3A4 basal expression by CCAAT enhancer-binding protein alpha and hepatocyte nuclear factor-3 gamma. Mol Pharmacol 63, 1180-1189. (Pubitemid 36529936)